Companion diagnostics partnering terms and agreements


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Companion diagnostics partnering terms and agreements

  1. 1. Companion Diagnostics Partnering Terms and Agreements The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understandingand unprecedented access to the companion diagnostics partnering deals and agreements entered into by theworlds leading healthcare companies. Trends in companion diagnostics partnering deals Companion diagnostics partnering agreement structureCompanion diagnostics partnering contract documents Top companion diagnostics deals by value Most activecompanion diagnostics dealmakers Description The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understandingand unprecedented access to the companion diagnostics partnering deals and agreements entered into by theworlds leading healthcare companies.The report provides a detailed understanding and analysis of how andwhy companies enter companion diagnostics partnering deals. The majority of deals are discovery ordevelopment stage whereby the licensee obtains a right or an option right to license the licensors companiondiagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, andcommercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into thenegotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst manysmaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of howpayments are triggered - contract documents provide this insight where press releases do not. This report contains over 1,000 links to online copies of actual companion diagnostics deals. In additioncontract documents as submitted to the Securities Exchange Commission by companies and their partners areavailable where they have been disclosed. Contract documents provide the answers to numerous questionsabout a prospective partners flexibility on a wide range of important issues, many of which will have asignificant impact on each partys ability to derive value from the deal. The initial chapters of this report provide an orientation of companion diagnostics dealmaking and businessactivities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trendsin companion diagnostics dealmaking since 2007. Chapter 3 provides a review of the leading companion diagnostics deals since 2007. Deals are listed byheadline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies.Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of companion diagnostics deals as well as contract documents availablein the public domain. Where available, each deal title links via Weblink to an online version of the actualcontract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of companion diagnostics partnering deals signedand announced since 2007, where a contract document is available in the public domain. The chapter isorganized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion,licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the dealrecord and where available, the contract document, providing easy access to each contract document ondemand.Companion Diagnostics Partnering Terms and Agreements
  2. 2. The report also includes numerous tables and figures that illustrate the trends and activities in companiondiagnostics partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theresearch, development and commercialization of companion diagnostics technologies and products. Report scope Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to companion diagnostics trends and structure of deals entered into by leadingcompanies worldwide. Companion Diagnostics Partnering Terms and Agreements includes: Trends in companion diagnostics dealmaking in the biopharma industry since 2007 Analysis of companiondiagnostics deal structure Links to online access to over 1,000 companion diagnostics deals The leadingcompanion diagnostics deals by value since 2007 Most active companion diagnostics dealmakers since 2007The leading companion diagnostics partnering resources In Companion Diagnostics Partnering Terms andAgreements, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Each deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive links to onlineaccess to over 1,000 companion diagnostics deals. Analyzing actual contract agreements allows assessment ofthe following: What are the precise companion diagnostics rights granted or optioned? What is actually granted by theagreement to the partner company? What exclusivity is granted? What is the payment structure for the deal?How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined?How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible fordevelopment, supply, and manufacture? How is confidentiality and publication managed? How are disputes tobe resolved? Under what conditions can the deal be terminated? What happens when there is a change ofownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clausesdoes the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal typeto deal type? Which jurisdiction does the company insist upon for agreement law? Benefits Companion Diagnostics Partnering Terms and Agreements provides the reader with the following keybenefits: In-depth understanding of companion diagnostics deal trends since 2007 Analysis of the structure ofcompanion diagnostics agreements with numerous real life case studies Comprehensive access to over 1,000actual companion diagnostics deals entered into by the worlds biopharma companies Detailed access to actualcompanion diagnostics deals and contracts enter into by the leading fifty bigpharma companies Understand thekey deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of yourproposed deal terms for partner companiestable Of Conrtentexecutive SummaryCompanion Diagnostics Partnering Terms and Agreements
  3. 3. chapter 1 - Introductionchapter 2 - Trends In Companion Diagnostics Dealmaking2.1. Introduction2.2. Companion Diagnostics Partnering Over The Years2.3. Bigpharma Companion Diagnostics Dealmaking Activity2.4. Bigpharma Not Active In Companion Diagnostics2.5. Companion Diagnostics Partnering By Deal Type2.6. Companion Diagnostics Partnering By Disease Type2.7 Average Deal Terms For Companion Diagnostics2.7.1 Companion Diagnostics Headline Values2.7.2 Companion Diagnostics Upfront Payments2.7.3 Companion Diagnostics Milestone Payments2.7.4 Companion Diagnostics Royalty Rateschapter 3 - Leading Companion Diagnostics Deals3.1. Introduction3.2. Top Companion Diagnostics Deals By Value3.3. Top Companion Diagnostics Deals Involving Bigpharmachapter 4 - Bigpharma Companion Diagnostics Deals4.1. Introduction4.2. How To Use Bigpharma Companion Diagnostics Partnering Deals4.3. Bigpharma Companion Diagnostics Partnering Companyprofilesabbottactavisalcon Labsallerganamgenapotexastellasastrazenecabaxter Internationalbayerbiogen Idecboehringer Ingelheimbristol-myers SquibbcelgenecephalonCompanion Diagnostics Partnering Terms and Agreements
  4. 4. chugaicsldaiichi Sankyodainippon Sumitomoeisaieli Lillyforest Laboratoriesgenzymegilead Sciencesglaxosmithklinehospirajohnson & Johnsonkyowa Hakko Kirinlundbeckmedamenarinimerck & Comerck Kgaamitsubishi Tanabemylannovartisnovo Nordisknycomed Pharmaotsukapfizerratiopharmrochesanofi-aventisserviershionogishiretakedatevaucbwatsonchapter 5 - Companion Diagnostics Dealmaking Directory5.1. Introduction5.2. Company A-z5.3. By Stage Of Developmentdiscoverypre-clinicalCompanion Diagnostics Partnering Terms and Agreements
  5. 5. phase Iphase Iiphase Iiiregistrationmarketed5.4. By Deal Typeasset And Product Purchasecollaborative R&dco-developmentco-marketingco-promotiondevelopmentdistributionevaluationjoint Venturelicensingmanufacturingmarketingoptionpromotionresearchsupply5.5. By Therapy Areahospital Carecardiovascularcentral Nervous Systemdentaldermatologygastrointestinalgenetic Disordersgenitourinaryhematologygenetic Disordersimmunologyinfectioninflammatorymetabolicmusculoskeletaloncologyophthalmicsrespiratorysensory Organanimal HealthCompanion Diagnostics Partnering Terms and Agreements
  6. 6. chapter 6 - Companion Diagnostics Partnering Resource Center6.1. Online Companion Diagnostics Partnering6.2. Companion Diagnostics Partnering Events6.3. Further Reading On Companion Diagnostics Dealmakingappendicesappendix 1 - Deal Type Definitionsappendix 2 - Example Companion Diagnostics Partnering Agreementabout Wildwood VenturesAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: Diagnostics Partnering Terms and Agreements